Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarin Pharmaceutical Inc.

https://www.biomarin.com/

Latest From BioMarin Pharmaceutical Inc.

Affibody And UCB Eye Humira’s Weak Spot In Hidradenitis Suppurativa

The rival firms are advancing separate biologic candidates that target IL-17 in a bid to treat the more than 60% of hidradenitis suppurativa patients who remain uncontrolled on AbbVie’s Humira, with recent trial readouts showing promise.

Clinical Trials Companies

Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target

Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.

Denmark C-Suite Speaks

Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets

Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.

Commercial Personalized Medicine

News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More

News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.

FDA Policy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
  • Other Names / Subsidiaries
    • Huxley Pharmaceuticals, Inc.
    • LEAD Therapeutics, Inc.
    • Prosensa Holding N.V
    • Zacharon Pharmaceuticals, Inc.
    • ZyStor Therapeutics, Inc.
UsernamePublicRestriction

Register